National Medical Care Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
National Medical Care verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 28.1%, während die Gewinne der Branche Healthcare jährlich um gewachsen und zwar um 20.3%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 10.5%. Die Eigenkapitalrendite von National Medical Care beträgt 17.8% und die Nettomargen betragen 22.5%.
Wichtige Informationen
28.1%
Wachstumsrate der Gewinne
28.1%
EPS-Wachstumsrate
Healthcare Wachstum der Industrie | 12.3% |
Wachstumsrate der Einnahmen | 10.5% |
Eigenkapitalrendite | 17.8% |
Netto-Marge | 22.5% |
Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
National Medical Care's (TADAWUL:4005) Solid Earnings May Rest On Weak Foundations
Oct 29We Think National Medical Care's (TADAWUL:4005) Robust Earnings Are Conservative
Mar 14Recent updates
National Medical Care's (TADAWUL:4005) Solid Earnings May Rest On Weak Foundations
Oct 29National Medical Care (TADAWUL:4005) Shareholders Will Want The ROCE Trajectory To Continue
Sep 25Analysts Are Updating Their National Medical Care Company (TADAWUL:4005) Estimates After Its Second-Quarter Results
Aug 06Getting In Cheap On National Medical Care Company (TADAWUL:4005) Is Unlikely
Jul 26National Medical Care Company's (TADAWUL:4005) Shares May Have Run Too Fast Too Soon
Apr 05We Think National Medical Care's (TADAWUL:4005) Robust Earnings Are Conservative
Mar 14National Medical Care (TADAWUL:4005) Is Very Good At Capital Allocation
Mar 13Some Confidence Is Lacking In National Medical Care Company's (TADAWUL:4005) P/E
Dec 27Returns On Capital Are Showing Encouraging Signs At National Medical Care (TADAWUL:4005)
Dec 05We Like These Underlying Return On Capital Trends At National Medical Care (TADAWUL:4005)
Aug 07Is National Medical Care Company (TADAWUL:4005) Worth ر.س107 Based On Its Intrinsic Value?
May 29Investors Will Want National Medical Care's (TADAWUL:4005) Growth In ROCE To Persist
May 08Investors Will Want National Medical Care's (TADAWUL:4005) Growth In ROCE To Persist
Dec 19A Look At The Fair Value Of National Medical Care Company (TADAWUL:4005)
Oct 19National Medical Care (TADAWUL:4005) Is Doing The Right Things To Multiply Its Share Price
Aug 15National Medical Care's (TADAWUL:4005) Returns On Capital Are Heading Higher
May 13Earnings Update: National Medical Care Company (TADAWUL:4005) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 03A Look At The Fair Value Of National Medical Care Company (TADAWUL:4005)
Feb 10Returns At National Medical Care (TADAWUL:4005) Appear To Be Weighed Down
Nov 10Returns On Capital At National Medical Care (TADAWUL:4005) Have Hit The Brakes
Jul 02Estimating The Intrinsic Value Of National Medical Care Company (TADAWUL:4005)
Apr 14Is National Medical Care Company (TADAWUL:4005) A Risky Dividend Stock?
Mar 25Will National Medical Care (TADAWUL:4005) Multiply In Value Going Forward?
Feb 23Update: National Medical Care (TADAWUL:4005) Stock Gained 25% In The Last Five Years
Feb 09National Medical Care Company's (TADAWUL:4005) Stock Been Rising But Financials Look Weak: Should Shareholders Be Worried?
Jan 27Calculating The Fair Value Of National Medical Care Company (TADAWUL:4005)
Jan 14Is National Medical Care Company's (TADAWUL:4005) 3.8% Dividend Sustainable?
Dec 25Does National Medical Care's (TADAWUL:4005) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 10What Kind Of Shareholders Hold The Majority In National Medical Care Company's (TADAWUL:4005) Shares?
Nov 24Aufschlüsselung der Einnahmen und Ausgaben
Wie National Medical Care Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Sep 24 | 1,221 | 274 | 174 | 0 |
30 Jun 24 | 1,171 | 288 | 150 | 0 |
31 Mar 24 | 1,119 | 266 | 132 | 0 |
31 Dec 23 | 1,082 | 241 | 124 | 0 |
30 Sep 23 | 1,034 | 233 | 94 | 0 |
30 Jun 23 | 997 | 202 | 110 | 0 |
31 Mar 23 | 968 | 196 | 103 | 0 |
31 Dec 22 | 918 | 170 | 98 | 0 |
30 Sep 22 | 882 | 151 | 104 | 0 |
30 Jun 22 | 857 | 142 | 94 | 0 |
31 Mar 22 | 843 | 131 | 93 | 0 |
31 Dec 21 | 845 | 136 | 88 | 0 |
30 Sep 21 | 844 | 122 | 99 | 0 |
30 Jun 21 | 845 | 105 | 104 | 0 |
31 Mar 21 | 828 | 100 | 113 | 0 |
31 Dec 20 | 809 | 97 | 107 | 0 |
30 Sep 20 | 780 | 95 | 86 | 0 |
30 Jun 20 | 740 | 95 | 78 | 0 |
31 Mar 20 | 724 | 83 | 72 | 0 |
31 Dec 19 | 708 | 80 | 73 | 0 |
30 Sep 19 | 705 | 65 | 73 | 0 |
30 Jun 19 | 707 | 60 | 72 | 0 |
31 Mar 19 | 737 | 67 | 76 | 0 |
31 Dec 18 | 764 | 62 | 81 | 0 |
30 Sep 18 | 810 | 81 | 92 | 0 |
30 Jun 18 | 842 | 96 | 92 | 0 |
31 Mar 18 | 859 | 95 | 96 | 0 |
31 Dec 17 | 855 | 85 | 100 | 0 |
30 Sep 17 | 817 | -8 | 125 | 0 |
30 Jun 17 | 806 | -7 | 126 | 0 |
31 Mar 17 | 849 | 33 | 119 | 0 |
31 Dec 16 | 901 | 50 | 124 | 0 |
30 Sep 16 | 931 | 155 | 90 | 0 |
30 Jun 16 | 945 | 153 | 91 | 0 |
31 Mar 16 | 913 | 136 | 95 | 0 |
31 Dec 15 | 879 | 131 | 87 | 0 |
30 Sep 15 | 853 | 106 | 96 | 0 |
30 Jun 15 | 820 | 102 | 94 | 0 |
31 Mar 15 | 772 | 91 | 94 | 0 |
31 Dec 14 | 734 | 95 | 81 | 0 |
30 Sep 14 | 703 | 106 | 70 | 0 |
30 Jun 14 | 660 | 103 | 58 | 0 |
31 Mar 14 | 623 | 94 | 42 | 0 |
31 Dec 13 | 586 | 92 | 38 | 0 |
Qualität der Erträge: 4005 einen hohen Anteil an unbarem Gewinn hat.
Wachsende Gewinnspanne: 4005Die aktuellen Gewinnspannen (22.5%) sind niedriger als im letzten Jahr (22.5%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 4005In den letzten 5 Jahren sind die Einnahmen von 28.1% pro Jahr erheblich gestiegen.
Beschleunigtes Wachstum: 4005Das Gewinnwachstum des Unternehmens im letzten Jahr (17.8%) liegt unter seinem 5-Jahres-Durchschnitt (28.1% pro Jahr).
Erträge im Vergleich zur Industrie: 4005 Das Gewinnwachstum im vergangenen Jahr (17.8%) übertraf das der Branche Healthcare 15.7% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 4005Die Eigenkapitalrendite des Unternehmens (17.8%) wird als niedrig angesehen.